NEU

NEUREN FPO NZ [NEU]
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid; and in Phase 2 clinical trial for the treatment of Angelman and Pitt Hopkins. In addition, it develops NNZ-2591, which is in preclinical trial stage for the treatment of Prader-Willi syndrome, Hypoxic Ischemic Encephalopathy, and SYNGAP1. The company was incorporated in 2001 and is based in Hawthorn East, Australia.
Healthcare · ASX Small Cap
$16.7600 -1.1%

Updated 22 Jul 2026 · Signals refresh every scan

Get alerts when NEU triggers a new signal
Free watchlist with daily scans for 2,200+ ASX stocks
Track NEU — Free

Active Signals

Bullish Signals

  • MACD momentum is losing steam
  • Stochastic just turned bullish from a low level — early reversal sign
  • Drifting lower — down 4.4% over the last 5 days
  • Beating the Small Ords index — relative strength of 1.36, so it's outpacing the pack
  • Volatility is contracting — like a spring being compressed, breakouts often follow
  • Trading above the 200-day average — the long-term trend is on your side
  • Cash positive / operating cashflow positive
  • Revenue in sharp decline (-81%)
  • Piotroski F-Score strong (7/9, low-confidence approx)
  • EPS estimates revised upward (+10pts)
  • Earnings in sharp decline (-88% QoQ)
  • CANSLIM A: Strong annual earnings CAGR (449%)
  • CANSLIM I: Institutional ownership (24%)
  • Healthy profit margins (47%)
  • Sentiment is mixed — no strong consensus either way
  • The bigger volume days are the up days — volume-weighted momentum is positive (2.68%/day)
  • Altman Z-Score grey zone (2.19, low-confidence approx)
  • RBA hiking (-3pts)

Risk Signals

  • Post-earnings drift: negative surprise (SUE -10)
  • Not enough chatter to gauge sentiment — defaulting to neutral
  • Long-term momentum is negative — down 35% over the past year
  • Earnings momentum has turned negative — worth checking what's behind it
  • Revenue declining at -81% — the top line is shrinking
Ask Scout AI about NEU
"What's driving NEU today?" "How does NEU compare to peers?" "Key risks for NEU?"
3 free messages/day · Unlimited with Pro

Recent Catalysts

NONE DAYBU recommended for approval in the European Union
NONE Application for quotation of securities - NEU
NONE Notification of cessation of securities - NEU

Recent ASX Announcements

2026-06-28 DAYBU recommended for approval in the European Union PRICE SENSITIVE
2026-06-18 Application for quotation of securities - NEU
2026-06-01 Notification of cessation of securities - NEU
2026-06-01 Notification regarding unquoted securities - NEU
2026-05-27 Results of Meeting

Key Metrics

$2.1B
Market Cap
662K
Avg Volume
0.7x
Vol Ratio
$11.00 — $22.98
52-Week Range
4.7%
Short Interest
N/A
Cash Runway
8.7%
ROE
47.1%
Profit Margin

CANSLIM Analysis

FactorRatingDetail
CCurrent EPSfailEPS Growth: -88%
AAnnual EarningspassCAGR: 449%
NNew Highs / Catalystsneutral
SSupply & DemandneutralFloat: 86%
LLeader vs LaggardpassRS: 20
IInstitutional SponsorshippassInst: 24%
MMarket DirectionneutralNeutral

Sector: Healthcare

101 tickers in this sector

View all Healthcare signals →Browse all ASX tickers A–Z →
Related Tickers
IDT +28.1%ADR +27.3%LDX +23.8%EYE +17.4%ECS -16.7%
Compare:NEU vs IDTNEU vs ADRNEU vs LDX
Scout Pro — Deeper Analysis for NEU
Try Pro free for 30 days
Share this analysis

Track NEU and 2,200+ ASX stocks

Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and exit management for every ASX small cap.

Open Dashboard — Free Free Screener
No credit card required